{"gene":"ITGA4","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":1995,"finding":"The ligand-binding sites of integrin α4β1 (CD49d/CD29) for VCAM-1 and fibronectin CS-1 were mapped to residues 108–268 of the α4 subunit using interspecies chimeras; epitopes B1 (residues 195–268) and B2 (residues 108–182) were associated with ligand binding, while Asp-130 of β1 was shown to be critical for binding to both VCAM-1 and CS-1, indicating shared binding mechanisms for the two ligands.","method":"Interspecies α4 chimeras expressed in mammalian cells, anti-α4 function-blocking mAb epitope mapping, D130A β1 mutagenesis with adhesion assays","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with chimera mapping and functional adhesion assays in a single study","pmids":["7531439"],"is_preprint":false},{"year":1996,"finding":"Transmembrane-4 superfamily proteins CD81, CD82, CD63, and CD53 specifically associate with integrin α4β1 (CD49d/CD29) as demonstrated by reciprocal co-immunoprecipitation and confocal co-localization; the association requires a ligand-competent α4 extracellular domain (abolished by adhesion-deficient D346E and D408E mutants) but is independent of the α4 cytoplasmic domain or divalent cations.","method":"Reciprocal co-immunoprecipitation, confocal microscopy, α4 adhesion-deficient point mutants (D346E, D408E) and cytoplasmic-domain deletion constructs","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — reciprocal Co-IP with mutagenesis and confocal colocalization in a single study","pmids":["8757325"],"is_preprint":false},{"year":1994,"finding":"VLA-4 (CD49d/CD29)-VCAM-1 adhesion prevents apoptosis of germinal center B cells; disruption of FDC–B cell clusters with anti-CD49d or anti-VCAM-1 mAb induces apoptosis, and adhesion to plastic-coated VCAM-1 diminishes apoptosis and synergizes with anti-IgM.","method":"mAb-mediated disruption of FDC–B cell clusters, adhesion to purified immobilized VCAM-1, apoptosis assays on human tonsil-derived GC B cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal experiments (cluster disruption + purified ligand adhesion + synergy assay) in primary human cells","pmids":["7511659"],"is_preprint":false},{"year":1996,"finding":"VLA-4 (CD49d/CD29) ligation on Jurkat T cells activates the phosphoinositide pathway and triggers a biphasic intracellular Ca2+ response; cross-linking of its counter-receptor VCAM-1 on endothelial cells produces the same Ca2+ mobilization, and cell–cell contact via VLA-4/VCAM-1 elicits mutual Ca2+ signaling in both cell types.","method":"Cross-linked anti-α4 mAb treatment of Jurkat cells and ECV 304 endothelial cells, spectrofluorimetry/confocal Ca2+ imaging with Fura-2, inositol 1,4,5-trisphosphate production assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal biochemical and imaging methods establishing downstream signaling mechanism","pmids":["9209507"],"is_preprint":false},{"year":1996,"finding":"α4β1 (CD49d/CD29) co-immobilized with anti-CD3 mAb costimulates freshly isolated human T cells to induce NF-AT, AP-1, and NF-κB transcription factor binding and secretion of IL-2, TNF-α, IFN-γ, and GM-CSF; α4β1 ligation alone is insufficient and does not alter the TCR activation threshold, indicating a distinct synergistic signaling pathway.","method":"Electromobility shift assays for transcription factors, cytokine ELISA, dose–response anti-CD3 titration with co-immobilized VCAM-1 or fibronectin CS-1, primary human peripheral blood T cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (EMSA + cytokine measurement + dose-response) establishing costimulatory signaling mechanism","pmids":["8757316"],"is_preprint":false},{"year":1994,"finding":"VLA-4 (CD49d/CD29)-mediated adhesion to fibronectin augments stimulated eosinophil degranulation (eosinophil peroxidase release); blocking CD49d with anti-VLA-4 mAb HP2/1 attenuates both fibronectin adhesion and EPO secretion induced by fMLF + cytochalasin B.","method":"Anti-VLA-4 mAb (HP2/1) blocking, eosinophil adhesion assay on FN-coated plates, eosinophil peroxidase release assay, primary human eosinophils","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 — specific mAb blocking with functional readout in primary cells; single lab","pmids":["8049081"],"is_preprint":false},{"year":1995,"finding":"VLA-4 (CD49d/CD29) on monocytes mediates transendothelial migration across IL-1-activated endothelium via VCAM-1 domains 1 and 4 independently of CD18; domain-1 mAb alone nearly completely blocks this CD18-independent migration, and combined domain-1 plus domain-4 blockade achieves complete inhibition.","method":"Monocyte transendothelial migration assay across CHO-VCAM transfectants and IL-1-activated HUVEC, domain-specific VCAM-1 blocking mAbs, CD18 and α4 blocking mAbs","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple blocking conditions across CHO transfectants and primary endothelium establishing pathway and domain specificity","pmids":["7545712"],"is_preprint":false},{"year":1995,"finding":"Upon IL-1 activation of endothelium, monocyte transendothelial migration in response to C5a, MIP-1α, RANTES, and PAF becomes CD18-independent and instead requires CD49d (VLA-4); combined anti-CD49d plus anti-CD18 fully blocks migration, whereas migration to MCP-1 is inhibited by endothelium-derived MCP-1 acting as an autocrine brake.","method":"mAb blocking of CD18 and α4 (CD49d) in chemokine-driven monocyte transendothelial migration assay, neutralization of HUVE-conditioned MCP-1","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — multiple chemokine conditions with complementary mAb blocking establishing alternate adhesion pathway","pmids":["7542307"],"is_preprint":false},{"year":1997,"finding":"Local intrapulmonary blockade of CD49d (α4 integrin) by intranasal mAb inhibits airway eosinophilia, IL-4/IL-5 release, mucus production, and hyperresponsiveness in allergic mice, whereas systemic (intraperitoneal) CD49d blockade only prevents eosinophilia; this identifies a CD49d-positive intrapulmonary leukocyte distinct from the eosinophil as the key effector cell of allergen-induced pulmonary inflammation.","method":"Intranasal vs. intraperitoneal anti-CD49d mAb administration in ovalbumin-sensitized mouse asthma model; BAL cell counts, cytokine measurement, methacholine challenge","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — route-controlled in vivo mAb blockade with multiple outcome measures establishing CD49d-positive intrapulmonary effector cell","pmids":["9399955"],"is_preprint":false},{"year":2000,"finding":"CD49d integrin expression is induced/upregulated during TNF-α– or LPS-induced maturation of monocyte-derived dendritic cells in an NF-κB– and p38 MAPK–dependent manner; upregulated CD49d confers mature MDDC with enhanced adhesion to fibronectin CS-1 and mediates their transendothelial migration.","method":"Northern blot and flow cytometry for CD49d during MDDC maturation, NF-κB inhibitor (N-acetylcysteine), p38 inhibitor (SB203580), MEK1/2 inhibitor (PD98059), adhesion assay to CS-1, transendothelial migration assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple pharmacological inhibitors with functional adhesion/migration readouts identifying signaling pathway controlling CD49d expression","pmids":["11035069"],"is_preprint":false},{"year":2002,"finding":"α4 integrin (CD49d)-mediated adhesion of B cells to fibronectin fragment H89 (α4β1 ligand) or FN-III4-5 protects against serum deprivation-induced apoptosis but not against IgM-triggered or Fas-mediated apoptosis; protection is reversed by anti-α4 mAb, indicating pathway-specific anti-apoptotic signaling.","method":"Adhesion of B cell lines (Ramos, Nalm-6, EHEB, IM-9) to recombinant fibronectin fragments H89 and FN-III4-5, viability assay, anti-α4 mAb blocking, comparison across three apoptosis induction pathways","journal":"Clinical and experimental immunology","confidence":"Medium","confidence_rationale":"Tier 2 — specific mAb blocking with multiple apoptosis-pathway comparisons; single lab","pmids":["11966761"],"is_preprint":false},{"year":2002,"finding":"Human NK cell rolling adhesion to porcine endothelial cells is mediated predominantly (>75% inhibition) by CD49d–CD106 (VLA-4/VCAM-1) interactions; static firm adhesion and transendothelial migration are also substantially dependent on CD49d–CD106 in addition to CD11a.","method":"Shear-stress flow adhesion assay and static adhesion assay with blocking mAbs to CD49d, CD106, CD62L, CD11a/CD18 on human NK cells and porcine EC; NK92 (FcγRIII–) cell line used to exclude Fc-dependent binding","journal":"Transplantation","confidence":"Medium","confidence_rationale":"Tier 2 — flow and static assays with multiple blocking conditions; single lab","pmids":["11907429"],"is_preprint":false},{"year":2004,"finding":"MIP-2-stimulated neutrophil mobilization from rat bone marrow is >75% dependent on CD49d; blockade of CD49d with neutralizing mAb or a specific antagonist dramatically inhibits chemokine-induced neutrophil release, while CD18 blockade paradoxically increases release, revealing contrasting roles for CD49d (in release) and CD18 (in retention).","method":"In situ perfusion of rat femoral bone marrow, blocking mAbs against CD49d and CD18, CD49d antagonist, neutrophil enumeration","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — novel in situ perfusion model with two independent CD49d inhibitors and complementary CD18 data; strong mechanistic conclusion","pmids":["15542579"],"is_preprint":false},{"year":2006,"finding":"Eosinophil adhesion to VCAM-1 module 1 (in 6d-VCAM-1 and 1-3VCAM-1 constructs) is mediated exclusively by α4β1 (CD49d/CD29), whereas adhesion to module 4 (4-7VCAM-1) is mediated by both α4β1 and αMβ2 (CD11b/CD18); PI3K inhibitors selectively block module-4-mediated adhesion, and IL-5 activation shifts dominance to αMβ2.","method":"Anti-α4, anti-αM, anti-β1, anti-CD18 mAb blocking; PI3K inhibitors; eosinophilic cell lines lacking αMβ2; static and flow adhesion assays with defined VCAM-1 module constructs; primary blood eosinophils","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution-like assay with engineered VCAM-1 domain constructs, multiple mAb and pharmacological inhibitors, orthogonal cell-line confirmation","pmids":["16943205"],"is_preprint":false},{"year":2005,"finding":"RUNX3 transcriptionally activates the CD49d (α4 integrin) gene promoter; RUNX3 overexpression correlates with increased CD49d mRNA and protein during monocyte-derived dendritic cell maturation, establishing RUNX3 as a transcriptional regulator of ITGA4 expression.","method":"CD49d promoter transactivation assay, RUNX3 overexpression, Northern/RT-PCR correlation in maturing MDDC","journal":"Immunobiology","confidence":"Medium","confidence_rationale":"Tier 2 — promoter assay plus expression correlation; single lab with functional promoter readout","pmids":["16164020"],"is_preprint":false},{"year":2006,"finding":"CD44 and CD49d physically associate in activated lymphocytes in vivo; this association allows CD44 to access FAK and allows CD49d to access lck and ezrin, so that ligand engagement of either molecule activates downstream kinases of both, synergistically enhancing lymphocyte motility, proliferation, and apoptosis resistance in autoimmune disease.","method":"Co-immunoprecipitation, anti-CD44 and anti-CD49d mAb blocking, co-culture/motility assays, draining LNC from murine alopecia areata model","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus mAb blocking with multiple functional readouts; single lab, in vivo autoimmune model","pmids":["17039568"],"is_preprint":false},{"year":2009,"finding":"The CD49d/CD29 integrin complex and CD38 are constitutively physically associated in primary CLL cells; CD38 enhances CD49d-mediated cell adhesion to VCAM-1 and fibronectin fragments, promotes Vav-1 phosphorylation and F-actin redistribution at adhesion sites, and increases apoptosis resistance in adherent CD49d+CD38+ vs. CD49d+CD38− cells.","method":"Cocapping, co-immunoprecipitation, CD38 transfection into CD49d+CD38− Mec-1 cells, adhesion assays on VCAM-1/fibronectin substrates, pVav-1 immunoblot, F-actin staining, apoptosis assays","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1–2 — reciprocal Co-IP, functional transfection rescue, and multiple orthogonal assays in primary CLL cells","pmids":["22289918"],"is_preprint":false},{"year":2013,"finding":"CD44 and CD49d cooperate in leukemia cell adhesion, migration, and apoptosis resistance by ligand-induced proximity that grants both molecules shared access to Src, FAK, paxillin, and via lck to the MAPK pathway; antiapoptotic molecule liberation requires wild-type cytoplasmic tails of both proteins; combined anti-CD44 plus anti-CD49d efficiently dislodges leukemia cells from bone marrow and spleen and enhances chemotherapy.","method":"CD49d transfection with point-mutated (FAK-binding and phosphorylation site ablated) variants into CD49d− EL4 lymphoma, CD44 transfection with ezrin-binding and tail-truncated mutants into CD44− Jurkat; ligand-blocking assays, FAK/Src/paxillin co-IP, in vitro/in vivo adhesion/migration/apoptosis assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis of both partners plus Co-IP signaling readouts and in vivo rescue experiments","pmids":["24127558"],"is_preprint":false},{"year":2017,"finding":"NOTCH1 pathway activation drives CD49d expression in CLL via NF-κB; stable transfection of the NOTCH1 intracellular domain into MEC-1 cells increases CD49d expression, pharmacological inhibition of NOTCH1 and/or NF-κB reduces NF-κB nuclear translocation and downmodulates CD49d, establishing a NOTCH1→NF-κB→CD49d regulatory axis.","method":"NOTCH1 intracellular domain stable transfection in MEC-1 cells, NOTCH1 and NF-κB pharmacological inhibitors, NF-κB nuclear translocation assay, CD49d flow cytometry and mRNA in primary CLL with mutated/wild-type NOTCH1","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function transfection plus complementary pathway inhibitors with mechanistic readout; replicated in primary patient cells","pmids":["28935990"],"is_preprint":false},{"year":2018,"finding":"VLA-4 (CD49d/CD29) undergoes inside-out activation upon BCR triggering in CD49d-positive CLL, reinforcing adhesion; ibrutinib reduces constitutive VLA-4 activation and adhesion but this can be overcome by exogenous BCR stimulation through a BTK-independent, PI3K-dependent mechanism.","method":"Inside-out VLA-4 activation assay, adhesion assays in vitro and in vivo with ibrutinib treatment, BCR crosslinking, BTK inhibition, PI3K inhibition, clinical CD49d expression monitoring in three ibrutinib-treated CLL cohorts","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo mechanistic experiments plus independent clinical cohort validation; strong Moderate evidence","pmids":["29301866"],"is_preprint":false},{"year":2022,"finding":"METTL3-mediated m6A methylation extends ITGA4 mRNA half-life, increasing ITGA4 protein expression and thereby enhancing AML cell homing and engraftment in bone marrow; a METTL3 inhibitor reverses this phenotype in vitro and in vivo.","method":"RNA sequencing, reverse-phase protein arrays, METTL3 knockdown/overexpression, mRNA stability assays, m6A methylation profiling, in vivo xenograft homing/engraftment models, METTL3 inhibitor treatment","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1–2 — mRNA stability mechanism demonstrated with multiple in vitro and in vivo methods; single lab with comprehensive mechanistic data","pmids":["36266324"],"is_preprint":false},{"year":2022,"finding":"The transcription factor FEV directly activates ITGA4 transcription in a dose-dependent manner in AML cells; FEV knockdown suppresses homing and proliferation, and natalizumab (anti-integrin α4) reduces migration and colony-forming ability of blasts and leukemic-initiating cells.","method":"FEV knockdown (AML cell lines), FEV dose-dependent ITGA4 promoter activation assay, natalizumab functional blockade of migration and colony-forming assays in primary and relapsed AML samples","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 — direct transcriptional activation assay plus loss-of-function and pharmacological blockade; single lab","pmids":["35875066"],"is_preprint":false},{"year":2023,"finding":"CAF-secreted laminin α5 engages ITGA4 on acinar cells to activate STAT3 signaling, driving acinar-to-ductal metaplasia (ADM) and pancreatic cancer initiation; the LAMA5/ITGA4/STAT3 axis was identified by integration of proteomics (CAF conditioned medium) and transcriptomics (acinar cell response), and validated by ITGA4 depletion in co-culture and mouse models.","method":"LC-MS/MS proteomics of CAF conditioned medium, RNA-seq of acinar cells, ITGA4 knockdown, confocal microscopy, immunoblotting, acinar organoid and explant co-culture with mCAFs in WT, KC, and KPC mice","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 1–2 — proteomics + transcriptomics integration with loss-of-function validation in multiple model systems","pmids":["38154529"],"is_preprint":false},{"year":2019,"finding":"CD9 overexpression in trabecular meshwork cells activates ITGA4 (integrin α4), leading to PI3K and Akt activation, decreased apoptosis, and attenuation of glaucoma-related cell death; ITGA4 acts downstream of CD9 in this anti-apoptotic signaling axis.","method":"Transcriptome and proteome profiling of iHTM vs. GTM3 cells, CD9 overexpression constructs, co-IP/signaling assays for ITGA4/PI3K/Akt, apoptosis assays","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function with downstream signaling readouts; single lab","pmids":["31680442"],"is_preprint":false},{"year":2015,"finding":"CD49d-positive neutrophils expressing VEGFR1 and CXCR4 require VLA-4 (CD49d/CD29) for crawling and emigration in response to VEGF-A but not to MIP-2 (CXCL2); intravital microscopy and transplantation-based angiogenesis models show that targeting CD49d impairs proangiogenic neutrophil recruitment and vessel neoformation.","method":"Intravital microscopy of mouse microcirculation, chimeric mice with impaired VEGFR1/VEGFR2 signaling, anti-CD49d blockade in avascular pancreatic islet transplantation model, FACS-sorted CD49d+ vs. CD49d− neutrophils in adhesion and chemotaxis assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vivo models (intravital imaging, chimeric mice, transplantation) plus in vitro cell sorting; replicated with independent approaches","pmids":["26286848"],"is_preprint":false},{"year":2019,"finding":"CD49d/CD29 (α4β1) integrin controls accumulation of plasmacytoid dendritic cells (pDCs) into the CNS during EAE; adoptive transfer experiments show pDCs are blood-recruited, and blocking CD49d drastically reduces CNS pDC numbers, while CD18 blockade has no effect, establishing a specific requirement for α4β1 but not β2 integrins.","method":"Adoptive transfer experiments, blocking anti-CD49d and anti-CD29 in vivo during acute EAE, flow cytometric quantification of CNS pDCs, ex vivo TLR-9 stimulation functional assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — adoptive transfer with specific mAb blocking; orthogonal integrin subunit blocking confirms β1-specific mechanism","pmids":["31318439"],"is_preprint":false},{"year":2004,"finding":"NOD mouse macrophages show defective LPS-induced upregulation of CD49d, reduced CD49d-mediated adhesion to fibronectin, and impaired migration; ERK1/2 negatively regulates macrophage CD49d expression and is hyperactive in NOD macrophages, contributing to their adhesion defect.","method":"Flow cytometry for CD49d on NOD vs. control macrophages, LPS stimulation, ERK1/2 pharmacological inhibition, fibronectin adhesion assay, peritoneal inflammation clearance assay","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological pathway dissection with functional adhesion readout; single lab","pmids":["15517611"],"is_preprint":false},{"year":2013,"finding":"CD49d promoter methylation inversely regulates CD49d expression in CLL; trisomy 12 CLL cells show near-complete absence of ITGA4 gene methylation and highest CD49d expression, while CD49d− cases are hypermethylated; treatment with the hypomethylating agent 5-aza-2′-deoxycytidine rescues CD49d expression in hypermethylated CLL cells.","method":"Bisulfite genomic sequencing of ITGA4 CpG sites, 5-aza-2′-deoxycytidine demethylation assay, flow cytometry across cytogenetic CLL groups (n=1200)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — direct bisulfite sequencing with pharmacological rescue of expression; large cohort with mechanistic demethylation experiment","pmids":["24068493"],"is_preprint":false},{"year":2001,"finding":"α4β1 (CD49d/CD29) and α5β1 integrins mediate β2-integrin-independent neutrophil recruitment to the lung in endotoxin-induced inflammation; combined anti-α4 + anti-β2 blockade inhibits parenchymal PMNL accumulation by 56% and BALF accumulation by 58%, and adding anti-α5 further reduces parenchymal accumulation to 79% inhibition.","method":"Intratracheal LPS model in Lewis rats, myeloperoxidase assay for parenchymal PMNL, BAL cell counts, combined and single mAb blocking with anti-α4, anti-α5, anti-β2","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — combinatorial mAb blocking design with multiple tissue compartment readouts; clear additive effects establish pathway","pmids":["11254723"],"is_preprint":false}],"current_model":"ITGA4 (CD49d) encodes the α4 subunit of the α4β1 (VLA-4) and α4β7 integrins, whose ligand-binding sites for VCAM-1 and fibronectin (CS-1) reside in α4 residues 108–268 with a critical β1-Asp130 contribution; ligand engagement activates the phosphoinositide/Ca2+ signaling cascade and costimulates T cell transcription factors (NF-AT, AP-1, NF-κB) and cytokine production; the integrin forms functional complexes with CD38, CD44, and tetraspanins (CD81/CD82/CD63/CD53), associates with FAK, lck, Src, and paxillin to drive adhesion-dependent survival and migration signals; its expression is transcriptionally regulated by RUNX3 and the NOTCH1→NF-κB axis and post-transcriptionally by METTL3-mediated m6A mRNA stabilization, and epigenetically silenced by promoter methylation; through VCAM-1 engagement, CD49d mediates leukocyte rolling, firm adhesion, and transendothelial migration in inflammation, allergy, autoimmunity, and hematopoietic cell trafficking, and drives AML homing/engraftment and CAF-induced pancreatic acinar-to-ductal transdifferentiation via a LAMA5/ITGA4/STAT3 axis."},"narrative":{"teleology":[{"year":1994,"claim":"Establishing that VLA-4–VCAM-1 engagement delivers a direct anti-apoptotic signal showed the integrin has a signaling function beyond simple adhesion, as disruption of follicular dendritic cell–B cell contacts with anti-CD49d or anti-VCAM-1 induced germinal center B cell apoptosis while purified VCAM-1 rescued survival.","evidence":"mAb-mediated disruption of FDC–B cell clusters and adhesion to immobilized VCAM-1, apoptosis assays in primary human tonsil GC B cells","pmids":["7511659"],"confidence":"High","gaps":["Downstream survival signaling molecules not identified","Whether β7 pairing can substitute for β1 in this context unknown"]},{"year":1995,"claim":"Mapping the ligand-binding determinants to α4 residues 108–268 and β1-Asp130 resolved which structural regions are responsible for dual recognition of VCAM-1 and fibronectin CS-1, establishing that the two ligands share overlapping binding mechanisms.","evidence":"Interspecies α4 chimeras, function-blocking mAb epitope mapping, D130A β1 mutagenesis with adhesion assays","pmids":["7531439"],"confidence":"High","gaps":["Atomic-resolution structure of the α4β1–ligand interface not determined","Relative contribution of each epitope to affinity not quantified"]},{"year":1995,"claim":"Demonstrating that monocyte transendothelial migration across activated endothelium can proceed via VLA-4/VCAM-1 independently of CD18 integrins established an alternative adhesion cascade for leukocyte extravasation, with VCAM-1 domains 1 and 4 acting as independent docking sites.","evidence":"Domain-specific VCAM-1 blocking mAbs, CD18 and α4 blocking in transendothelial migration assays across CHO-VCAM transfectants and IL-1-activated HUVEC","pmids":["7545712","7542307"],"confidence":"High","gaps":["Whether domain-1 and domain-4 engage the same α4 epitope or distinct sites not resolved","Relative contribution of α4β7 vs. α4β1 in this transmigration not tested"]},{"year":1996,"claim":"Showing that VLA-4 ligation activates the phosphoinositide pathway and triggers bidirectional Ca²⁺ signaling between T cells and endothelial cells revealed that VLA-4 engagement initiates classical second-messenger cascades, while the finding that VLA-4 costimulates NF-AT, AP-1, and NF-κB downstream of TCR established its role as a bona fide T cell costimulatory molecule.","evidence":"Spectrofluorimetry/confocal Ca²⁺ imaging with Fura-2, IP3 assays in Jurkat cells; EMSA for transcription factors and cytokine ELISA with co-immobilized VCAM-1/CS-1 in primary T cells","pmids":["9209507","8757316"],"confidence":"High","gaps":["Proximal kinase linking VLA-4 to PLC/IP3 not identified","Whether costimulation requires sustained adhesion or transient ligation not tested"]},{"year":1996,"claim":"Discovery that tetraspanins CD81, CD82, CD63, and CD53 specifically associate with α4β1 through the ligand-competent extracellular domain of α4—independently of the cytoplasmic tail—revealed a supramolecular organization principle in which tetraspanin-enriched microdomains scaffold integrin signaling platforms.","evidence":"Reciprocal co-immunoprecipitation, confocal co-localization, adhesion-deficient α4 mutants (D346E, D408E) and cytoplasmic-tail deletion constructs","pmids":["8757325"],"confidence":"High","gaps":["Functional consequence of tetraspanin association for downstream signaling not directly tested","Stoichiometry and direct vs. bridged interaction not resolved"]},{"year":1997,"claim":"Intrapulmonary anti-CD49d blockade inhibited airway eosinophilia, cytokine release, mucus production, and hyperresponsiveness in allergic mice—while systemic blockade only affected eosinophilia—identifying a CD49d-positive intrapulmonary effector cell as the critical mediator of allergen-induced airway inflammation.","evidence":"Intranasal vs. intraperitoneal anti-CD49d mAb in ovalbumin-sensitized mouse model; BAL counts, cytokines, methacholine challenge","pmids":["9399955"],"confidence":"High","gaps":["Identity of the intrapulmonary CD49d+ effector cell not definitively established","Whether α4β7 contributes in addition to α4β1 not distinguished"]},{"year":2001,"claim":"Showing that α4β1 and α5β1 mediate β2-integrin-independent neutrophil recruitment to inflamed lung parenchyma via combinatorial mAb blocking expanded the paradigm that β1 integrins serve as an alternative neutrophil emigration pathway in tissue-specific inflammation.","evidence":"Intratracheal LPS in rats, myeloperoxidase assay, BAL counts, combined anti-α4/anti-α5/anti-β2 mAb blocking","pmids":["11254723"],"confidence":"High","gaps":["Specific ligand(s) engaged by α4β1 on pulmonary endothelium/matrix not identified","Kinetics of α4 vs. β2 utilization during disease progression not studied"]},{"year":2004,"claim":"Demonstrating that CD49d is required for chemokine-induced neutrophil mobilization from bone marrow—with >75% dependence—while CD18 promotes retention established opposing roles for these integrins in controlling the bone marrow neutrophil reserve.","evidence":"In situ perfusion of rat femoral bone marrow with MIP-2, blocking mAbs and CD49d antagonist","pmids":["15542579"],"confidence":"High","gaps":["Specific VCAM-1 or other stromal ligand mediating retention not identified","Whether this mechanism applies to other hematopoietic lineages not tested"]},{"year":2005,"claim":"Identification of RUNX3 as a transcriptional activator of the ITGA4 promoter provided the first transcription-factor-level explanation for CD49d upregulation during dendritic cell maturation.","evidence":"CD49d promoter transactivation assay, RUNX3 overexpression, Northern/RT-PCR in maturing monocyte-derived DCs","pmids":["16164020"],"confidence":"Medium","gaps":["RUNX3 binding site in the ITGA4 promoter not mapped by ChIP","Whether RUNX3 is necessary (loss-of-function) not tested"]},{"year":2006,"claim":"Resolving that VCAM-1 module 1 is engaged exclusively by α4β1 while module 4 is engaged by both α4β1 and αMβ2 clarified the molecular basis of module-specific adhesion and revealed PI3K-dependent regulation of the module-4 pathway, with IL-5 shifting integrin usage toward αMβ2.","evidence":"Defined VCAM-1 module constructs, mAb blocking, PI3K inhibitors, eosinophilic cell lines lacking αMβ2, primary eosinophils","pmids":["16943205"],"confidence":"High","gaps":["Structural basis for module specificity not determined","Whether PI3K acts on integrin activation state or surface expression not resolved"]},{"year":2009,"claim":"Discovering that CD38 constitutively associates with CD49d in CLL and enhances VCAM-1 adhesion, Vav-1 phosphorylation, and survival signaling explained the synergistic prognostic impact of CD38+CD49d+ co-expression in CLL.","evidence":"Cocapping, co-immunoprecipitation, CD38 transfection into Mec-1 cells, adhesion/apoptosis assays, pVav-1 immunoblot in primary CLL","pmids":["22289918"],"confidence":"High","gaps":["Whether CD38 enzymatic activity is required or just its physical presence not resolved","Structural interface between CD38 and α4β1 unknown"]},{"year":2013,"claim":"Elucidating that CD44 and CD49d cooperate through ligand-induced proximity to share downstream kinases (FAK, Src, paxillin, lck→MAPK)—requiring intact cytoplasmic tails of both—and that combined blockade dislodges leukemia cells in vivo, provided a mechanistic framework for adhesion-based therapeutic targeting.","evidence":"Mutagenesis of CD49d (FAK-binding/phosphorylation sites) and CD44 (ezrin-binding/tail-truncated) in lymphoma/Jurkat cells, Co-IP, in vivo adhesion/migration assays","pmids":["24127558"],"confidence":"High","gaps":["Direct structural contact between CD44 and CD49d not demonstrated","Relative contribution of each kinase to survival vs. migration not dissected"]},{"year":2013,"claim":"Demonstrating that ITGA4 promoter CpG methylation inversely controls CD49d expression—with demethylation rescuing expression—established an epigenetic layer of ITGA4 regulation and linked trisomy 12 CLL to constitutive CD49d overexpression via hypomethylation.","evidence":"Bisulfite genomic sequencing, 5-aza-2′-deoxycytidine demethylation rescue, flow cytometry across ~1200 CLL cases","pmids":["24068493"],"confidence":"High","gaps":["Which specific CpG sites are functionally decisive not narrowed down","Methyltransferase(s) responsible not identified"]},{"year":2017,"claim":"Identifying a NOTCH1→NF-κB→CD49d transcriptional axis in CLL explained how gain-of-function NOTCH1 mutations drive CD49d overexpression and the associated aggressive clinical phenotype.","evidence":"NOTCH1 intracellular domain stable transfection in MEC-1, NOTCH1/NF-κB pharmacological inhibitors, NF-κB nuclear translocation assay, primary CLL with mutated NOTCH1","pmids":["28935990"],"confidence":"High","gaps":["Whether NF-κB binds the ITGA4 promoter directly or through intermediary factors not shown","Contribution of non-canonical NF-κB not assessed"]},{"year":2018,"claim":"Showing that BCR signaling triggers VLA-4 inside-out activation through a PI3K-dependent, BTK-independent mechanism—and that ibrutinib reduces but cannot fully suppress this—revealed why CD49d+ CLL may resist BTK-inhibitor therapy through sustained adhesion.","evidence":"Inside-out VLA-4 activation assays, ibrutinib treatment, PI3K/BTK inhibitors, in vivo models, three independent clinical CLL cohorts","pmids":["29301866"],"confidence":"High","gaps":["Identity of the PI3K isoform responsible not determined","Whether this mechanism operates in other B cell malignancies not tested"]},{"year":2022,"claim":"Discovery that METTL3-mediated m6A methylation stabilizes ITGA4 mRNA, increasing protein expression and AML homing/engraftment, introduced a post-transcriptional regulatory layer and identified METTL3 inhibition as a strategy to target ITGA4-dependent leukemia–niche interactions.","evidence":"METTL3 knockdown/overexpression, mRNA stability assays, m6A profiling, in vivo xenograft homing models, METTL3 inhibitor treatment","pmids":["36266324"],"confidence":"High","gaps":["Specific m6A site(s) on ITGA4 mRNA not mapped","m6A reader protein mediating stabilization not identified"]},{"year":2023,"claim":"Identification of a CAF-secreted LAMA5/ITGA4/STAT3 axis driving acinar-to-ductal metaplasia expanded ITGA4 function beyond immune cell biology into stromal-epithelial crosstalk in early pancreatic carcinogenesis.","evidence":"LC-MS/MS proteomics, RNA-seq, ITGA4 knockdown, acinar organoid/explant co-culture, KC and KPC mouse models","pmids":["38154529"],"confidence":"High","gaps":["Whether ITGA4 pairs with β1 or β7 in acinar cells not specified","Downstream STAT3 targets mediating ADM not identified","Whether ITGA4 blockade prevents tumor progression beyond ADM not tested"]},{"year":null,"claim":"A high-resolution structural model of the full α4β1 ectodomain in complex with VCAM-1 or fibronectin CS-1 remains unresolved, and the precise mechanisms by which tetraspanin and CD38/CD44 supramolecular assemblies organize α4β1 signaling at the nanoscale are still unknown.","evidence":"","pmids":[],"confidence":"Low","gaps":["No atomic-resolution α4β1–ligand co-structure","Nanoscale organization of the α4β1–tetraspanin–CD38–CD44 signaling platform unresolved","Relative in vivo contributions of α4β1 vs. α4β7 in most tissue contexts not systematically addressed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,6,7,11,13]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,4,23]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[15,17]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,3,11,16]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,6,7,8,24,25,28]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,19,22,23]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,6,11,13]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,10,17]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,10,22]}],"complexes":["VLA-4 (α4β1 integrin)","α4β7 integrin","Tetraspanin-enriched microdomain (CD81/CD82/CD63/CD53–α4β1)"],"partners":["ITGB1","ITGB7","VCAM1","CD38","CD44","CD81","CD82","PTK2"],"other_free_text":[]},"mechanistic_narrative":"ITGA4 (CD49d) encodes the α4 integrin subunit that pairs with β1 (forming VLA-4/α4β1) or β7 to mediate leukocyte adhesion, rolling, firm attachment, and transendothelial migration through binding to VCAM-1 and fibronectin CS-1, with the ligand-binding site mapped to α4 residues 108–268 and a critical contribution from β1-Asp130 [PMID:7531439]. VLA-4 ligation activates the phosphoinositide/Ca²⁺ signaling cascade [PMID:9209507], costimulates TCR-dependent activation of NF-AT, AP-1, and NF-κB transcription factors with cytokine secretion [PMID:8757316], and delivers anti-apoptotic survival signals in germinal center B cells and leukemia cells through cooperation with CD44, CD38, and tetraspanins (CD81/CD82/CD63/CD53) that connect to FAK, Src, lck, and paxillin signaling networks [PMID:7511659, PMID:24127558, PMID:22289918, PMID:8757325]. ITGA4 expression is transcriptionally regulated by RUNX3, the NOTCH1–NF-κB axis, and FEV, epigenetically controlled by promoter CpG methylation, and post-transcriptionally stabilized by METTL3-mediated m6A modification, with its functional output governing diverse processes including inflammatory cell recruitment to lung, CNS, and bone marrow, hematopoietic stem/progenitor cell mobilization, AML homing and engraftment, and CAF-driven acinar-to-ductal metaplasia via a LAMA5/ITGA4/STAT3 axis [PMID:28935990, PMID:24068493, PMID:36266324, PMID:31318439, PMID:38154529]."},"prefetch_data":{"uniprot":{"accession":"P13612","full_name":"Integrin alpha-4","aliases":["CD49 antigen-like family member D","Integrin alpha-IV","VLA-4 subunit alpha"],"length_aa":1032,"mass_kda":114.9,"function":"Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415). ITGA4:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). Integrin ITGA4:ITGB1 represses PRKCA-mediated L-type voltage-gated channel Ca(2+) influx and ROCK-mediated calcium sensitivity in vascular smooth muscle cells via its interaction with SVEP1, thereby inhibiting vasocontraction (PubMed:35802072)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/P13612/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ITGA4","classification":"Not Classified","n_dependent_lines":22,"n_total_lines":1208,"dependency_fraction":0.018211920529801324},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ITGA4","total_profiled":1310},"omim":[{"mim_id":"617685","title":"CADHERIN 26; CDH26","url":"https://www.omim.org/entry/617685"},{"mim_id":"614372","title":"MANNOSE-BINDING LECTIN DEFICIENCY; MBLD","url":"https://www.omim.org/entry/614372"},{"mim_id":"608381","title":"CERAMIDE KINASE-LIKE; CERKL","url":"https://www.omim.org/entry/608381"},{"mim_id":"607901","title":"FERM DOMAIN-CONTAINING KINDLIN 3; FERMT3","url":"https://www.omim.org/entry/607901"},{"mim_id":"606870","title":"JUNCTIONAL ADHESION MOLECULE 2; JAM2","url":"https://www.omim.org/entry/606870"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":44.0},{"tissue":"lymphoid tissue","ntpm":69.0}],"url":"https://www.proteinatlas.org/search/ITGA4"},"hgnc":{"alias_symbol":["CD49d"],"prev_symbol":["CD49D"]},"alphafold":{"accession":"P13612","domains":[{"cath_id":"2.130.10.130","chopping":"37-465","consensus_level":"medium","plddt":93.4437,"start":37,"end":465},{"cath_id":"2.60.40.1460","chopping":"468-590_600-619","consensus_level":"high","plddt":85.6338,"start":468,"end":619},{"cath_id":"2.60.40.1510","chopping":"632-769","consensus_level":"high","plddt":83.0336,"start":632,"end":769},{"cath_id":"2.60.40.1530","chopping":"775-861_879-969","consensus_level":"high","plddt":86.1085,"start":775,"end":969}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P13612","model_url":"https://alphafold.ebi.ac.uk/files/AF-P13612-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P13612-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ITGA4","jax_strain_url":"https://www.jax.org/strain/search?query=ITGA4"},"sequence":{"accession":"P13612","fasta_url":"https://rest.uniprot.org/uniprotkb/P13612.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P13612/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P13612"}},"corpus_meta":[{"pmid":"7511659","id":"PMC_7511659","title":"Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7511659","citation_count":274,"is_preprint":false},{"pmid":"8757325","id":"PMC_8757325","title":"Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin alpha 4 beta 1 (CD49d/CD29).","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8757325","citation_count":200,"is_preprint":false},{"pmid":"26286848","id":"PMC_26286848","title":"Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26286848","citation_count":197,"is_preprint":false},{"pmid":"19228923","id":"PMC_19228923","title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19228923","citation_count":166,"is_preprint":false},{"pmid":"19383907","id":"PMC_19383907","title":"CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19383907","citation_count":138,"is_preprint":false},{"pmid":"9399955","id":"PMC_9399955","title":"Blockade of CD49d (alpha4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9399955","citation_count":126,"is_preprint":false},{"pmid":"7531439","id":"PMC_7531439","title":"Identification of putative ligand-binding sites of the integrin alpha 4 beta 1 (VLA-4, CD49d/CD29).","date":"1995","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/7531439","citation_count":119,"is_preprint":false},{"pmid":"18309158","id":"PMC_18309158","title":"Intracarotid injection of fluorescence activated cell-sorted CD49d-positive neural stem cells improves targeted cell delivery and behavior after stroke in a mouse stroke model.","date":"2008","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/18309158","citation_count":118,"is_preprint":false},{"pmid":"20525890","id":"PMC_20525890","title":"CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20525890","citation_count":93,"is_preprint":false},{"pmid":"8683134","id":"PMC_8683134","title":"L- and P-selectins, but not CD49d (VLA-4) integrins, mediate monocyte initial attachment to TNF-alpha-activated vascular endothelium under flow in vitro.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8683134","citation_count":84,"is_preprint":false},{"pmid":"15542579","id":"PMC_15542579","title":"The CXC chemokine MIP-2 stimulates neutrophil mobilization from the rat bone marrow in a CD49d-dependent manner.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15542579","citation_count":83,"is_preprint":false},{"pmid":"29301866","id":"PMC_29301866","title":"Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29301866","citation_count":82,"is_preprint":false},{"pmid":"36266324","id":"PMC_36266324","title":"METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/36266324","citation_count":79,"is_preprint":false},{"pmid":"22289918","id":"PMC_22289918","title":"The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22289918","citation_count":77,"is_preprint":false},{"pmid":"11254723","id":"PMC_11254723","title":"The alpha 4 beta 1 (very late antigen (VLA)-4, CD49d/CD29) and alpha 5 beta 1 (VLA-5, CD49e/CD29) integrins mediate beta 2 (CD11/CD18) integrin-independent neutrophil recruitment to endotoxin-induced lung inflammation.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11254723","citation_count":68,"is_preprint":false},{"pmid":"11035069","id":"PMC_11035069","title":"Maturation-dependent expression and function of the CD49d integrin on monocyte-derived human dendritic cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11035069","citation_count":67,"is_preprint":false},{"pmid":"18641015","id":"PMC_18641015","title":"CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.","date":"2008","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/18641015","citation_count":62,"is_preprint":false},{"pmid":"8049081","id":"PMC_8049081","title":"Augmentation of stimulated eosinophil degranulation by VLA-4 (CD49d)-mediated adhesion to fibronectin.","date":"1994","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8049081","citation_count":59,"is_preprint":false},{"pmid":"23116545","id":"PMC_23116545","title":"Evaluating the performance of fibronectin 1 (FN1), integrin α4β1 (ITGA4), syndecan-2 (SDC2), and glycoprotein CD44 as the potential biomarkers of oral squamous cell carcinoma (OSCC).","date":"2012","source":"Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/23116545","citation_count":57,"is_preprint":false},{"pmid":"11063837","id":"PMC_11063837","title":"VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.","date":"2000","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/11063837","citation_count":56,"is_preprint":false},{"pmid":"21033217","id":"PMC_21033217","title":"Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients.","date":"2010","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21033217","citation_count":55,"is_preprint":false},{"pmid":"9003249","id":"PMC_9003249","title":"Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis.","date":"1997","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/9003249","citation_count":54,"is_preprint":false},{"pmid":"20876348","id":"PMC_20876348","title":"Cutting edge: CD49d+ neutrophils induce FcepsilonRI expression on lung dendritic cells in a mouse model of postviral asthma.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20876348","citation_count":52,"is_preprint":false},{"pmid":"8757316","id":"PMC_8757316","title":"Alpha 4 beta 1 (CD49d/CD29) integrin costimulation of human T cells enhances transcription factor and cytokine induction in the absence of altered sensitivity to anti-CD3 stimulation.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8757316","citation_count":50,"is_preprint":false},{"pmid":"24068493","id":"PMC_24068493","title":"CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/24068493","citation_count":50,"is_preprint":false},{"pmid":"32006000","id":"PMC_32006000","title":"CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32006000","citation_count":48,"is_preprint":false},{"pmid":"20098455","id":"PMC_20098455","title":"CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.","date":"2010","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/20098455","citation_count":47,"is_preprint":false},{"pmid":"7542307","id":"PMC_7542307","title":"IL-1 activation of endothelium supports VLA-4 (CD49d/CD29)-mediated monocyte transendothelial migration to C5a, MIP-1 alpha, RANTES, and PAF but inhibits migration to MCP-1: a regulatory role for endothelium-derived MCP-1.","date":"1995","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/7542307","citation_count":47,"is_preprint":false},{"pmid":"25902909","id":"PMC_25902909","title":"Hypermethylation of ITGA4, TFPI2 and VIMENTIN promoters is increased in inflamed colon tissue: putative risk markers for colitis-associated cancer.","date":"2015","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25902909","citation_count":46,"is_preprint":false},{"pmid":"25239835","id":"PMC_25239835","title":"CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.","date":"2014","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25239835","citation_count":44,"is_preprint":false},{"pmid":"16943205","id":"PMC_16943205","title":"Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d/29) and alphaMbeta2 (CD11b/18) of eosinophils.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16943205","citation_count":43,"is_preprint":false},{"pmid":"9552005","id":"PMC_9552005","title":"Adhesion molecule mechanisms mediating monocyte migration through synovial fibroblast and endothelium barriers: role for CD11/CD18, very late antigen-4 (CD49d/CD29), very late antigen-5 (CD49e/CD29), and vascular cell adhesion molecule-1 (CD106).","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9552005","citation_count":43,"is_preprint":false},{"pmid":"19553613","id":"PMC_19553613","title":"Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.","date":"2009","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19553613","citation_count":42,"is_preprint":false},{"pmid":"8020569","id":"PMC_8020569","title":"Regulated expression of p150,95 (CD11c/CD18; alpha X/beta 2) and VLA-4 (CD49d/CD29; alpha 4/beta 1) integrins during myeloid cell differentiation.","date":"1994","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8020569","citation_count":41,"is_preprint":false},{"pmid":"14604954","id":"PMC_14604954","title":"In vivo exit of c-kit+/CD49d(hi)/beta7+ mucosal mast cell precursors from the bone marrow following infection with the intestinal nematode Trichinella spiralis.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14604954","citation_count":40,"is_preprint":false},{"pmid":"11238023","id":"PMC_11238023","title":"Blockade of CD49d inhibits allergic airway pathologies independent of effects on leukocyte recruitment.","date":"2001","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11238023","citation_count":38,"is_preprint":false},{"pmid":"7545712","id":"PMC_7545712","title":"Domains 1 and 4 of vascular cell adhesion molecule-1 (CD106) both support very late activation antigen-4 (CD49d/CD29)-dependent monocyte transendothelial migration.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7545712","citation_count":36,"is_preprint":false},{"pmid":"25048781","id":"PMC_25048781","title":"Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.","date":"2014","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/25048781","citation_count":34,"is_preprint":false},{"pmid":"28662951","id":"PMC_28662951","title":"CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination.","date":"2017","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/28662951","citation_count":34,"is_preprint":false},{"pmid":"28935990","id":"PMC_28935990","title":"NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28935990","citation_count":34,"is_preprint":false},{"pmid":"8709639","id":"PMC_8709639","title":"Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8709639","citation_count":34,"is_preprint":false},{"pmid":"9209507","id":"PMC_9209507","title":"Clustering the adhesion molecules VLA-4 (CD49d/CD29) in Jurkat T cells or VCAM-1 (CD106) in endothelial (ECV 304) cells activates the phosphoinositide pathway and triggers Ca2+ mobilization.","date":"1997","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9209507","citation_count":34,"is_preprint":false},{"pmid":"22050952","id":"PMC_22050952","title":"CD49d expression as a promising biomarker to monitor natalizumab efficacy.","date":"2011","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/22050952","citation_count":31,"is_preprint":false},{"pmid":"11355415","id":"PMC_11355415","title":"Post-mortem markers of sepsis: an immunohistochemical study using VLA-4 (CD49d/CD29) and ICAM-1 (CD54) for the detection of sepsis-induced lung injury.","date":"2001","source":"International journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11355415","citation_count":30,"is_preprint":false},{"pmid":"12584052","id":"PMC_12584052","title":"C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusion.","date":"2003","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/12584052","citation_count":30,"is_preprint":false},{"pmid":"11907429","id":"PMC_11907429","title":"Rolling adhesion of human NK cells to porcine endothelial cells mainly relies on CD49d-CD106 interactions.","date":"2002","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/11907429","citation_count":28,"is_preprint":false},{"pmid":"10837366","id":"PMC_10837366","title":"Glucocorticoid receptor activation reduces CD11b and CD49d levels on murine eosinophils: characterization and functional relevance.","date":"2000","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10837366","citation_count":28,"is_preprint":false},{"pmid":"38154529","id":"PMC_38154529","title":"Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis.","date":"2023","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/38154529","citation_count":27,"is_preprint":false},{"pmid":"10030843","id":"PMC_10030843","title":"The role of alpha4 (CD49d) and beta2 (CD18) integrins in eosinophil and neutrophil migration to allergic lung inflammation in the Brown Norway rat.","date":"1999","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10030843","citation_count":27,"is_preprint":false},{"pmid":"1709118","id":"PMC_1709118","title":"ICAM-2 peptides mediate lymphocyte adhesion by binding to CD11a/CD18 and CD49d/CD29 integrins.","date":"1991","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/1709118","citation_count":27,"is_preprint":false},{"pmid":"17039568","id":"PMC_17039568","title":"In vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17039568","citation_count":24,"is_preprint":false},{"pmid":"24127558","id":"PMC_24127558","title":"Cooperativity of CD44 and CD49d in leukemia cell homing, migration, and survival offers a means for therapeutic attack.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24127558","citation_count":24,"is_preprint":false},{"pmid":"31680442","id":"PMC_31680442","title":"Integrative transcriptomic and proteomic analysis reveals CD9/ITGA4/PI3K-Akt axis mediates trabecular meshwork cell apoptosis in human glaucoma.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31680442","citation_count":23,"is_preprint":false},{"pmid":"11966761","id":"PMC_11966761","title":"Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors.","date":"2002","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11966761","citation_count":23,"is_preprint":false},{"pmid":"21060781","id":"PMC_21060781","title":"ADAM2 interactions with mouse eggs and cell lines expressing α4/α9 (ITGA4/ITGA9) integrins: implications for integrin-based adhesion and fertilization.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21060781","citation_count":23,"is_preprint":false},{"pmid":"28386906","id":"PMC_28386906","title":"CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.","date":"2017","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/28386906","citation_count":22,"is_preprint":false},{"pmid":"19011162","id":"PMC_19011162","title":"Plasma from patients with sepsis up-regulates the expression of CD49d and CD64 on blood neutrophils.","date":"2008","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19011162","citation_count":22,"is_preprint":false},{"pmid":"1383369","id":"PMC_1383369","title":"Regulation of T cell proliferation by anti-CD49d and anti-CD29 monoclonal antibodies.","date":"1992","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/1383369","citation_count":21,"is_preprint":false},{"pmid":"26559905","id":"PMC_26559905","title":"CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.","date":"2015","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/26559905","citation_count":21,"is_preprint":false},{"pmid":"21598361","id":"PMC_21598361","title":"LPAR1 and ITGA4 regulate peripheral blood monocyte counts.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21598361","citation_count":20,"is_preprint":false},{"pmid":"9507736","id":"PMC_9507736","title":"Importance of CD49d-VCAM interactions in human monocyte adhesion to porcine endothelium.","date":"1998","source":"Xenotransplantation","url":"https://pubmed.ncbi.nlm.nih.gov/9507736","citation_count":20,"is_preprint":false},{"pmid":"9476917","id":"PMC_9476917","title":"CD49d expression and function on allergen-stimulated T cells from blood and airway.","date":"1998","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9476917","citation_count":19,"is_preprint":false},{"pmid":"16164020","id":"PMC_16164020","title":"RUNX3 regulates the activity of the CD11a and CD49d integrin gene promoters.","date":"2005","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/16164020","citation_count":18,"is_preprint":false},{"pmid":"26664665","id":"PMC_26664665","title":"CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy.","date":"2015","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/26664665","citation_count":18,"is_preprint":false},{"pmid":"25060807","id":"PMC_25060807","title":"CD49d Treg cells with high suppressive capacity are remarkably less efficient on activated CD45RA- than on naive CD45RA+ Teff cells.","date":"2014","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25060807","citation_count":18,"is_preprint":false},{"pmid":"28378895","id":"PMC_28378895","title":"Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.","date":"2017","source":"Cytometry. Part B, Clinical cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/28378895","citation_count":17,"is_preprint":false},{"pmid":"33914894","id":"PMC_33914894","title":"CD49d marks Th1 and Tfh-like antigen-specific CD4+ T cells during Plasmodium chabaudi infection.","date":"2021","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33914894","citation_count":17,"is_preprint":false},{"pmid":"28455608","id":"PMC_28455608","title":"Expansion of CD11b+Ly6Ghigh and CD11b+CD49d+ myeloid cells with suppressive potential in mice with chronic inflammation and light-at-night-induced circadian disruption.","date":"2017","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/28455608","citation_count":17,"is_preprint":false},{"pmid":"22731992","id":"PMC_22731992","title":"Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1α and MCP-1 in GM-CSF-treated human primary eosinophils.","date":"2012","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/22731992","citation_count":17,"is_preprint":false},{"pmid":"12969328","id":"PMC_12969328","title":"Differential roles of VLA-4(CD49d/CD29) and LFA-1(CD11a/CD18) integrins and E- and P-selectin during developing and established active or adoptively transferred adjuvant arthritis in the rat.","date":"2003","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12969328","citation_count":17,"is_preprint":false},{"pmid":"11504693","id":"PMC_11504693","title":"Intrinsic AHR in IL-5 transgenic mice is dependent on CD4(+) cells and CD49d-mediated signaling.","date":"2001","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11504693","citation_count":16,"is_preprint":false},{"pmid":"22159714","id":"PMC_22159714","title":"The CD49d+/high subpopulation from isolated human breast sarcoma spheres possesses tumor-initiating ability.","date":"2011","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22159714","citation_count":16,"is_preprint":false},{"pmid":"17689671","id":"PMC_17689671","title":"ITGA4 polymorphisms and susceptibility to multiple sclerosis.","date":"2007","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/17689671","citation_count":16,"is_preprint":false},{"pmid":"11063841","id":"PMC_11063841","title":"CD4(+)CD45RO(+)CD49d(high) cells are involved in the pathogenesis of relapsing-remitting multiple sclerosis.","date":"2000","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/11063841","citation_count":15,"is_preprint":false},{"pmid":"20663947","id":"PMC_20663947","title":"The role of 9-O-acetylated ganglioside D3 (CD60) and {alpha}4{beta}1 (CD49d) expression in predicting the survival of patients with Sezary syndrome.","date":"2010","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/20663947","citation_count":14,"is_preprint":false},{"pmid":"27464494","id":"PMC_27464494","title":"MiR-30s Family Inhibit the Proliferation and Apoptosis in Human Coronary Artery Endothelial Cells Through Targeting the 3'UTR Region of ITGA4 and PLCG1.","date":"2016","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27464494","citation_count":13,"is_preprint":false},{"pmid":"15990174","id":"PMC_15990174","title":"Hyaluronate receptor (CD44) and integrin alpha4 (CD49d) are up-regulated on T cells during MS relapses.","date":"2005","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/15990174","citation_count":13,"is_preprint":false},{"pmid":"19259978","id":"PMC_19259978","title":"Association of the alpha4 integrin subunit gene (ITGA4) with autism.","date":"2009","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19259978","citation_count":13,"is_preprint":false},{"pmid":"36117589","id":"PMC_36117589","title":"Candesartan Reduces Neuronal Apoptosis Caused by Ischemic Stroke via Regulating the FFAR1/ITGA4 Pathway.","date":"2022","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36117589","citation_count":12,"is_preprint":false},{"pmid":"32802392","id":"PMC_32802392","title":"ITGA4 gene methylation status in chronic lymphocytic leukemia.","date":"2020","source":"Future science OA","url":"https://pubmed.ncbi.nlm.nih.gov/32802392","citation_count":12,"is_preprint":false},{"pmid":"29769839","id":"PMC_29769839","title":"A Novel Association of Polymorphism in the ITGA4 Gene Encoding the VLA-4 α4 Subunit with Increased Risk of Alzheimer's Disease.","date":"2018","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29769839","citation_count":12,"is_preprint":false},{"pmid":"12847241","id":"PMC_12847241","title":"CD49d overexpression and T cell autoimmunity.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12847241","citation_count":11,"is_preprint":false},{"pmid":"36254221","id":"PMC_36254221","title":"Lymph Node Metastasis-Related Gene ITGA4 Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Regulating Tumor Immune Microenvironment.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36254221","citation_count":11,"is_preprint":false},{"pmid":"37457377","id":"PMC_37457377","title":"Detection of DNA Methylation in Gene Loci ASTN1, DLX1, ITGA4, RXFP3, SOX17, and ZNF671 for Diagnosis of Cervical Cancer.","date":"2023","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/37457377","citation_count":11,"is_preprint":false},{"pmid":"31861635","id":"PMC_31861635","title":"Multiple Sclerosis CD49d+CD154+ As Myelin-Specific Lymphocytes Induced During Remyelination.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31861635","citation_count":10,"is_preprint":false},{"pmid":"18562709","id":"PMC_18562709","title":"Identification of ITGA4/ITGB7 and ITGAE/ITGB7 expressing subsets of decidual dendritic-like cells within distinct microdomains of the pregnant mouse uterus.","date":"2008","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/18562709","citation_count":10,"is_preprint":false},{"pmid":"31318439","id":"PMC_31318439","title":"CD49d/CD29-integrin controls the accumulation of plasmacytoid dendritic cells into the CNS during neuroinflammation.","date":"2019","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31318439","citation_count":10,"is_preprint":false},{"pmid":"11953028","id":"PMC_11953028","title":"Low oxygen tension and autologous plasma enhance T-cell proliferation and CD49d expression density in serum-free media.","date":"2001","source":"Cytotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/11953028","citation_count":10,"is_preprint":false},{"pmid":"27514846","id":"PMC_27514846","title":"Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.","date":"2016","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/27514846","citation_count":9,"is_preprint":false},{"pmid":"39841806","id":"PMC_39841806","title":"Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice.","date":"2025","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39841806","citation_count":9,"is_preprint":false},{"pmid":"35284127","id":"PMC_35284127","title":"The early predictive effect of low expression of the ITGA4 in colorectal cancer.","date":"2022","source":"Journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35284127","citation_count":9,"is_preprint":false},{"pmid":"29955944","id":"PMC_29955944","title":"In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.","date":"2018","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/29955944","citation_count":9,"is_preprint":false},{"pmid":"34247018","id":"PMC_34247018","title":"Reduced frequency and functional potency of CD49d- T regulatory cells in patients with newly diagnosed type 2 diabetes mellitus.","date":"2021","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34247018","citation_count":8,"is_preprint":false},{"pmid":"24034934","id":"PMC_24034934","title":"Increasing the ex vivo antigen-specific IFN-γ production in subpopulations of T cells and NKp46+ cells by anti-CD28, anti-CD49d and recombinant IL-12 costimulation in cattle vaccinated with recombinant proteins from Mycobacterium avium subspecies paratuberculosis.","date":"2013","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24034934","citation_count":8,"is_preprint":false},{"pmid":"12753772","id":"PMC_12753772","title":"Alpha4-integrin (CD49d) expression on bovine peripheral blood neutrophils is related to inflammation of the respiratory system.","date":"2003","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/12753772","citation_count":8,"is_preprint":false},{"pmid":"10791904","id":"PMC_10791904","title":"Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.","date":"1999","source":"Journal of hematotherapy & stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/10791904","citation_count":8,"is_preprint":false},{"pmid":"35875066","id":"PMC_35875066","title":"FEV Maintains Homing and Expansion by Activating ITGA4 Transcription in Primary and Relapsed AML.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35875066","citation_count":7,"is_preprint":false},{"pmid":"15517611","id":"PMC_15517611","title":"Defective up-regulation of CD49d in final maturation of NOD mouse macrophages.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15517611","citation_count":7,"is_preprint":false},{"pmid":"22902398","id":"PMC_22902398","title":"Circulating CD35(-)/CD49d(+) neutrophils in influenza virus infection patients.","date":"2012","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22902398","citation_count":7,"is_preprint":false},{"pmid":"30061889","id":"PMC_30061889","title":"Identification of Human B-1 Helper T Cells With a Th1-Like Memory Phenotype and High Integrin CD49d Expression.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30061889","citation_count":7,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52985,"output_tokens":8052,"usd":0.139868},"stage2":{"model":"claude-opus-4-6","input_tokens":12046,"output_tokens":4807,"usd":0.270608},"total_usd":0.410476,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"The ligand-binding sites of integrin α4β1 (CD49d/CD29) for VCAM-1 and fibronectin CS-1 were mapped to residues 108–268 of the α4 subunit using interspecies chimeras; epitopes B1 (residues 195–268) and B2 (residues 108–182) were associated with ligand binding, while Asp-130 of β1 was shown to be critical for binding to both VCAM-1 and CS-1, indicating shared binding mechanisms for the two ligands.\",\n      \"method\": \"Interspecies α4 chimeras expressed in mammalian cells, anti-α4 function-blocking mAb epitope mapping, D130A β1 mutagenesis with adhesion assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with chimera mapping and functional adhesion assays in a single study\",\n      \"pmids\": [\"7531439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Transmembrane-4 superfamily proteins CD81, CD82, CD63, and CD53 specifically associate with integrin α4β1 (CD49d/CD29) as demonstrated by reciprocal co-immunoprecipitation and confocal co-localization; the association requires a ligand-competent α4 extracellular domain (abolished by adhesion-deficient D346E and D408E mutants) but is independent of the α4 cytoplasmic domain or divalent cations.\",\n      \"method\": \"Reciprocal co-immunoprecipitation, confocal microscopy, α4 adhesion-deficient point mutants (D346E, D408E) and cytoplasmic-domain deletion constructs\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP with mutagenesis and confocal colocalization in a single study\",\n      \"pmids\": [\"8757325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"VLA-4 (CD49d/CD29)-VCAM-1 adhesion prevents apoptosis of germinal center B cells; disruption of FDC–B cell clusters with anti-CD49d or anti-VCAM-1 mAb induces apoptosis, and adhesion to plastic-coated VCAM-1 diminishes apoptosis and synergizes with anti-IgM.\",\n      \"method\": \"mAb-mediated disruption of FDC–B cell clusters, adhesion to purified immobilized VCAM-1, apoptosis assays on human tonsil-derived GC B cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal experiments (cluster disruption + purified ligand adhesion + synergy assay) in primary human cells\",\n      \"pmids\": [\"7511659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"VLA-4 (CD49d/CD29) ligation on Jurkat T cells activates the phosphoinositide pathway and triggers a biphasic intracellular Ca2+ response; cross-linking of its counter-receptor VCAM-1 on endothelial cells produces the same Ca2+ mobilization, and cell–cell contact via VLA-4/VCAM-1 elicits mutual Ca2+ signaling in both cell types.\",\n      \"method\": \"Cross-linked anti-α4 mAb treatment of Jurkat cells and ECV 304 endothelial cells, spectrofluorimetry/confocal Ca2+ imaging with Fura-2, inositol 1,4,5-trisphosphate production assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal biochemical and imaging methods establishing downstream signaling mechanism\",\n      \"pmids\": [\"9209507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"α4β1 (CD49d/CD29) co-immobilized with anti-CD3 mAb costimulates freshly isolated human T cells to induce NF-AT, AP-1, and NF-κB transcription factor binding and secretion of IL-2, TNF-α, IFN-γ, and GM-CSF; α4β1 ligation alone is insufficient and does not alter the TCR activation threshold, indicating a distinct synergistic signaling pathway.\",\n      \"method\": \"Electromobility shift assays for transcription factors, cytokine ELISA, dose–response anti-CD3 titration with co-immobilized VCAM-1 or fibronectin CS-1, primary human peripheral blood T cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (EMSA + cytokine measurement + dose-response) establishing costimulatory signaling mechanism\",\n      \"pmids\": [\"8757316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"VLA-4 (CD49d/CD29)-mediated adhesion to fibronectin augments stimulated eosinophil degranulation (eosinophil peroxidase release); blocking CD49d with anti-VLA-4 mAb HP2/1 attenuates both fibronectin adhesion and EPO secretion induced by fMLF + cytochalasin B.\",\n      \"method\": \"Anti-VLA-4 mAb (HP2/1) blocking, eosinophil adhesion assay on FN-coated plates, eosinophil peroxidase release assay, primary human eosinophils\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — specific mAb blocking with functional readout in primary cells; single lab\",\n      \"pmids\": [\"8049081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"VLA-4 (CD49d/CD29) on monocytes mediates transendothelial migration across IL-1-activated endothelium via VCAM-1 domains 1 and 4 independently of CD18; domain-1 mAb alone nearly completely blocks this CD18-independent migration, and combined domain-1 plus domain-4 blockade achieves complete inhibition.\",\n      \"method\": \"Monocyte transendothelial migration assay across CHO-VCAM transfectants and IL-1-activated HUVEC, domain-specific VCAM-1 blocking mAbs, CD18 and α4 blocking mAbs\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple blocking conditions across CHO transfectants and primary endothelium establishing pathway and domain specificity\",\n      \"pmids\": [\"7545712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Upon IL-1 activation of endothelium, monocyte transendothelial migration in response to C5a, MIP-1α, RANTES, and PAF becomes CD18-independent and instead requires CD49d (VLA-4); combined anti-CD49d plus anti-CD18 fully blocks migration, whereas migration to MCP-1 is inhibited by endothelium-derived MCP-1 acting as an autocrine brake.\",\n      \"method\": \"mAb blocking of CD18 and α4 (CD49d) in chemokine-driven monocyte transendothelial migration assay, neutralization of HUVE-conditioned MCP-1\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple chemokine conditions with complementary mAb blocking establishing alternate adhesion pathway\",\n      \"pmids\": [\"7542307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Local intrapulmonary blockade of CD49d (α4 integrin) by intranasal mAb inhibits airway eosinophilia, IL-4/IL-5 release, mucus production, and hyperresponsiveness in allergic mice, whereas systemic (intraperitoneal) CD49d blockade only prevents eosinophilia; this identifies a CD49d-positive intrapulmonary leukocyte distinct from the eosinophil as the key effector cell of allergen-induced pulmonary inflammation.\",\n      \"method\": \"Intranasal vs. intraperitoneal anti-CD49d mAb administration in ovalbumin-sensitized mouse asthma model; BAL cell counts, cytokine measurement, methacholine challenge\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — route-controlled in vivo mAb blockade with multiple outcome measures establishing CD49d-positive intrapulmonary effector cell\",\n      \"pmids\": [\"9399955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD49d integrin expression is induced/upregulated during TNF-α– or LPS-induced maturation of monocyte-derived dendritic cells in an NF-κB– and p38 MAPK–dependent manner; upregulated CD49d confers mature MDDC with enhanced adhesion to fibronectin CS-1 and mediates their transendothelial migration.\",\n      \"method\": \"Northern blot and flow cytometry for CD49d during MDDC maturation, NF-κB inhibitor (N-acetylcysteine), p38 inhibitor (SB203580), MEK1/2 inhibitor (PD98059), adhesion assay to CS-1, transendothelial migration assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological inhibitors with functional adhesion/migration readouts identifying signaling pathway controlling CD49d expression\",\n      \"pmids\": [\"11035069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"α4 integrin (CD49d)-mediated adhesion of B cells to fibronectin fragment H89 (α4β1 ligand) or FN-III4-5 protects against serum deprivation-induced apoptosis but not against IgM-triggered or Fas-mediated apoptosis; protection is reversed by anti-α4 mAb, indicating pathway-specific anti-apoptotic signaling.\",\n      \"method\": \"Adhesion of B cell lines (Ramos, Nalm-6, EHEB, IM-9) to recombinant fibronectin fragments H89 and FN-III4-5, viability assay, anti-α4 mAb blocking, comparison across three apoptosis induction pathways\",\n      \"journal\": \"Clinical and experimental immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — specific mAb blocking with multiple apoptosis-pathway comparisons; single lab\",\n      \"pmids\": [\"11966761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Human NK cell rolling adhesion to porcine endothelial cells is mediated predominantly (>75% inhibition) by CD49d–CD106 (VLA-4/VCAM-1) interactions; static firm adhesion and transendothelial migration are also substantially dependent on CD49d–CD106 in addition to CD11a.\",\n      \"method\": \"Shear-stress flow adhesion assay and static adhesion assay with blocking mAbs to CD49d, CD106, CD62L, CD11a/CD18 on human NK cells and porcine EC; NK92 (FcγRIII–) cell line used to exclude Fc-dependent binding\",\n      \"journal\": \"Transplantation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — flow and static assays with multiple blocking conditions; single lab\",\n      \"pmids\": [\"11907429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MIP-2-stimulated neutrophil mobilization from rat bone marrow is >75% dependent on CD49d; blockade of CD49d with neutralizing mAb or a specific antagonist dramatically inhibits chemokine-induced neutrophil release, while CD18 blockade paradoxically increases release, revealing contrasting roles for CD49d (in release) and CD18 (in retention).\",\n      \"method\": \"In situ perfusion of rat femoral bone marrow, blocking mAbs against CD49d and CD18, CD49d antagonist, neutrophil enumeration\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — novel in situ perfusion model with two independent CD49d inhibitors and complementary CD18 data; strong mechanistic conclusion\",\n      \"pmids\": [\"15542579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Eosinophil adhesion to VCAM-1 module 1 (in 6d-VCAM-1 and 1-3VCAM-1 constructs) is mediated exclusively by α4β1 (CD49d/CD29), whereas adhesion to module 4 (4-7VCAM-1) is mediated by both α4β1 and αMβ2 (CD11b/CD18); PI3K inhibitors selectively block module-4-mediated adhesion, and IL-5 activation shifts dominance to αMβ2.\",\n      \"method\": \"Anti-α4, anti-αM, anti-β1, anti-CD18 mAb blocking; PI3K inhibitors; eosinophilic cell lines lacking αMβ2; static and flow adhesion assays with defined VCAM-1 module constructs; primary blood eosinophils\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution-like assay with engineered VCAM-1 domain constructs, multiple mAb and pharmacological inhibitors, orthogonal cell-line confirmation\",\n      \"pmids\": [\"16943205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RUNX3 transcriptionally activates the CD49d (α4 integrin) gene promoter; RUNX3 overexpression correlates with increased CD49d mRNA and protein during monocyte-derived dendritic cell maturation, establishing RUNX3 as a transcriptional regulator of ITGA4 expression.\",\n      \"method\": \"CD49d promoter transactivation assay, RUNX3 overexpression, Northern/RT-PCR correlation in maturing MDDC\",\n      \"journal\": \"Immunobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter assay plus expression correlation; single lab with functional promoter readout\",\n      \"pmids\": [\"16164020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD44 and CD49d physically associate in activated lymphocytes in vivo; this association allows CD44 to access FAK and allows CD49d to access lck and ezrin, so that ligand engagement of either molecule activates downstream kinases of both, synergistically enhancing lymphocyte motility, proliferation, and apoptosis resistance in autoimmune disease.\",\n      \"method\": \"Co-immunoprecipitation, anti-CD44 and anti-CD49d mAb blocking, co-culture/motility assays, draining LNC from murine alopecia areata model\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus mAb blocking with multiple functional readouts; single lab, in vivo autoimmune model\",\n      \"pmids\": [\"17039568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The CD49d/CD29 integrin complex and CD38 are constitutively physically associated in primary CLL cells; CD38 enhances CD49d-mediated cell adhesion to VCAM-1 and fibronectin fragments, promotes Vav-1 phosphorylation and F-actin redistribution at adhesion sites, and increases apoptosis resistance in adherent CD49d+CD38+ vs. CD49d+CD38− cells.\",\n      \"method\": \"Cocapping, co-immunoprecipitation, CD38 transfection into CD49d+CD38− Mec-1 cells, adhesion assays on VCAM-1/fibronectin substrates, pVav-1 immunoblot, F-actin staining, apoptosis assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal Co-IP, functional transfection rescue, and multiple orthogonal assays in primary CLL cells\",\n      \"pmids\": [\"22289918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD44 and CD49d cooperate in leukemia cell adhesion, migration, and apoptosis resistance by ligand-induced proximity that grants both molecules shared access to Src, FAK, paxillin, and via lck to the MAPK pathway; antiapoptotic molecule liberation requires wild-type cytoplasmic tails of both proteins; combined anti-CD44 plus anti-CD49d efficiently dislodges leukemia cells from bone marrow and spleen and enhances chemotherapy.\",\n      \"method\": \"CD49d transfection with point-mutated (FAK-binding and phosphorylation site ablated) variants into CD49d− EL4 lymphoma, CD44 transfection with ezrin-binding and tail-truncated mutants into CD44− Jurkat; ligand-blocking assays, FAK/Src/paxillin co-IP, in vitro/in vivo adhesion/migration/apoptosis assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis of both partners plus Co-IP signaling readouts and in vivo rescue experiments\",\n      \"pmids\": [\"24127558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NOTCH1 pathway activation drives CD49d expression in CLL via NF-κB; stable transfection of the NOTCH1 intracellular domain into MEC-1 cells increases CD49d expression, pharmacological inhibition of NOTCH1 and/or NF-κB reduces NF-κB nuclear translocation and downmodulates CD49d, establishing a NOTCH1→NF-κB→CD49d regulatory axis.\",\n      \"method\": \"NOTCH1 intracellular domain stable transfection in MEC-1 cells, NOTCH1 and NF-κB pharmacological inhibitors, NF-κB nuclear translocation assay, CD49d flow cytometry and mRNA in primary CLL with mutated/wild-type NOTCH1\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function transfection plus complementary pathway inhibitors with mechanistic readout; replicated in primary patient cells\",\n      \"pmids\": [\"28935990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"VLA-4 (CD49d/CD29) undergoes inside-out activation upon BCR triggering in CD49d-positive CLL, reinforcing adhesion; ibrutinib reduces constitutive VLA-4 activation and adhesion but this can be overcome by exogenous BCR stimulation through a BTK-independent, PI3K-dependent mechanism.\",\n      \"method\": \"Inside-out VLA-4 activation assay, adhesion assays in vitro and in vivo with ibrutinib treatment, BCR crosslinking, BTK inhibition, PI3K inhibition, clinical CD49d expression monitoring in three ibrutinib-treated CLL cohorts\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo mechanistic experiments plus independent clinical cohort validation; strong Moderate evidence\",\n      \"pmids\": [\"29301866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"METTL3-mediated m6A methylation extends ITGA4 mRNA half-life, increasing ITGA4 protein expression and thereby enhancing AML cell homing and engraftment in bone marrow; a METTL3 inhibitor reverses this phenotype in vitro and in vivo.\",\n      \"method\": \"RNA sequencing, reverse-phase protein arrays, METTL3 knockdown/overexpression, mRNA stability assays, m6A methylation profiling, in vivo xenograft homing/engraftment models, METTL3 inhibitor treatment\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mRNA stability mechanism demonstrated with multiple in vitro and in vivo methods; single lab with comprehensive mechanistic data\",\n      \"pmids\": [\"36266324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The transcription factor FEV directly activates ITGA4 transcription in a dose-dependent manner in AML cells; FEV knockdown suppresses homing and proliferation, and natalizumab (anti-integrin α4) reduces migration and colony-forming ability of blasts and leukemic-initiating cells.\",\n      \"method\": \"FEV knockdown (AML cell lines), FEV dose-dependent ITGA4 promoter activation assay, natalizumab functional blockade of migration and colony-forming assays in primary and relapsed AML samples\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct transcriptional activation assay plus loss-of-function and pharmacological blockade; single lab\",\n      \"pmids\": [\"35875066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CAF-secreted laminin α5 engages ITGA4 on acinar cells to activate STAT3 signaling, driving acinar-to-ductal metaplasia (ADM) and pancreatic cancer initiation; the LAMA5/ITGA4/STAT3 axis was identified by integration of proteomics (CAF conditioned medium) and transcriptomics (acinar cell response), and validated by ITGA4 depletion in co-culture and mouse models.\",\n      \"method\": \"LC-MS/MS proteomics of CAF conditioned medium, RNA-seq of acinar cells, ITGA4 knockdown, confocal microscopy, immunoblotting, acinar organoid and explant co-culture with mCAFs in WT, KC, and KPC mice\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — proteomics + transcriptomics integration with loss-of-function validation in multiple model systems\",\n      \"pmids\": [\"38154529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD9 overexpression in trabecular meshwork cells activates ITGA4 (integrin α4), leading to PI3K and Akt activation, decreased apoptosis, and attenuation of glaucoma-related cell death; ITGA4 acts downstream of CD9 in this anti-apoptotic signaling axis.\",\n      \"method\": \"Transcriptome and proteome profiling of iHTM vs. GTM3 cells, CD9 overexpression constructs, co-IP/signaling assays for ITGA4/PI3K/Akt, apoptosis assays\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with downstream signaling readouts; single lab\",\n      \"pmids\": [\"31680442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD49d-positive neutrophils expressing VEGFR1 and CXCR4 require VLA-4 (CD49d/CD29) for crawling and emigration in response to VEGF-A but not to MIP-2 (CXCL2); intravital microscopy and transplantation-based angiogenesis models show that targeting CD49d impairs proangiogenic neutrophil recruitment and vessel neoformation.\",\n      \"method\": \"Intravital microscopy of mouse microcirculation, chimeric mice with impaired VEGFR1/VEGFR2 signaling, anti-CD49d blockade in avascular pancreatic islet transplantation model, FACS-sorted CD49d+ vs. CD49d− neutrophils in adhesion and chemotaxis assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo models (intravital imaging, chimeric mice, transplantation) plus in vitro cell sorting; replicated with independent approaches\",\n      \"pmids\": [\"26286848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CD49d/CD29 (α4β1) integrin controls accumulation of plasmacytoid dendritic cells (pDCs) into the CNS during EAE; adoptive transfer experiments show pDCs are blood-recruited, and blocking CD49d drastically reduces CNS pDC numbers, while CD18 blockade has no effect, establishing a specific requirement for α4β1 but not β2 integrins.\",\n      \"method\": \"Adoptive transfer experiments, blocking anti-CD49d and anti-CD29 in vivo during acute EAE, flow cytometric quantification of CNS pDCs, ex vivo TLR-9 stimulation functional assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — adoptive transfer with specific mAb blocking; orthogonal integrin subunit blocking confirms β1-specific mechanism\",\n      \"pmids\": [\"31318439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NOD mouse macrophages show defective LPS-induced upregulation of CD49d, reduced CD49d-mediated adhesion to fibronectin, and impaired migration; ERK1/2 negatively regulates macrophage CD49d expression and is hyperactive in NOD macrophages, contributing to their adhesion defect.\",\n      \"method\": \"Flow cytometry for CD49d on NOD vs. control macrophages, LPS stimulation, ERK1/2 pharmacological inhibition, fibronectin adhesion assay, peritoneal inflammation clearance assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection with functional adhesion readout; single lab\",\n      \"pmids\": [\"15517611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD49d promoter methylation inversely regulates CD49d expression in CLL; trisomy 12 CLL cells show near-complete absence of ITGA4 gene methylation and highest CD49d expression, while CD49d− cases are hypermethylated; treatment with the hypomethylating agent 5-aza-2′-deoxycytidine rescues CD49d expression in hypermethylated CLL cells.\",\n      \"method\": \"Bisulfite genomic sequencing of ITGA4 CpG sites, 5-aza-2′-deoxycytidine demethylation assay, flow cytometry across cytogenetic CLL groups (n=1200)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct bisulfite sequencing with pharmacological rescue of expression; large cohort with mechanistic demethylation experiment\",\n      \"pmids\": [\"24068493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"α4β1 (CD49d/CD29) and α5β1 integrins mediate β2-integrin-independent neutrophil recruitment to the lung in endotoxin-induced inflammation; combined anti-α4 + anti-β2 blockade inhibits parenchymal PMNL accumulation by 56% and BALF accumulation by 58%, and adding anti-α5 further reduces parenchymal accumulation to 79% inhibition.\",\n      \"method\": \"Intratracheal LPS model in Lewis rats, myeloperoxidase assay for parenchymal PMNL, BAL cell counts, combined and single mAb blocking with anti-α4, anti-α5, anti-β2\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — combinatorial mAb blocking design with multiple tissue compartment readouts; clear additive effects establish pathway\",\n      \"pmids\": [\"11254723\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ITGA4 (CD49d) encodes the α4 subunit of the α4β1 (VLA-4) and α4β7 integrins, whose ligand-binding sites for VCAM-1 and fibronectin (CS-1) reside in α4 residues 108–268 with a critical β1-Asp130 contribution; ligand engagement activates the phosphoinositide/Ca2+ signaling cascade and costimulates T cell transcription factors (NF-AT, AP-1, NF-κB) and cytokine production; the integrin forms functional complexes with CD38, CD44, and tetraspanins (CD81/CD82/CD63/CD53), associates with FAK, lck, Src, and paxillin to drive adhesion-dependent survival and migration signals; its expression is transcriptionally regulated by RUNX3 and the NOTCH1→NF-κB axis and post-transcriptionally by METTL3-mediated m6A mRNA stabilization, and epigenetically silenced by promoter methylation; through VCAM-1 engagement, CD49d mediates leukocyte rolling, firm adhesion, and transendothelial migration in inflammation, allergy, autoimmunity, and hematopoietic cell trafficking, and drives AML homing/engraftment and CAF-induced pancreatic acinar-to-ductal transdifferentiation via a LAMA5/ITGA4/STAT3 axis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ITGA4 (CD49d) encodes the α4 integrin subunit that pairs with β1 (forming VLA-4/α4β1) or β7 to mediate leukocyte adhesion, rolling, firm attachment, and transendothelial migration through binding to VCAM-1 and fibronectin CS-1, with the ligand-binding site mapped to α4 residues 108–268 and a critical contribution from β1-Asp130 [PMID:7531439]. VLA-4 ligation activates the phosphoinositide/Ca²⁺ signaling cascade [PMID:9209507], costimulates TCR-dependent activation of NF-AT, AP-1, and NF-κB transcription factors with cytokine secretion [PMID:8757316], and delivers anti-apoptotic survival signals in germinal center B cells and leukemia cells through cooperation with CD44, CD38, and tetraspanins (CD81/CD82/CD63/CD53) that connect to FAK, Src, lck, and paxillin signaling networks [PMID:7511659, PMID:24127558, PMID:22289918, PMID:8757325]. ITGA4 expression is transcriptionally regulated by RUNX3, the NOTCH1–NF-κB axis, and FEV, epigenetically controlled by promoter CpG methylation, and post-transcriptionally stabilized by METTL3-mediated m6A modification, with its functional output governing diverse processes including inflammatory cell recruitment to lung, CNS, and bone marrow, hematopoietic stem/progenitor cell mobilization, AML homing and engraftment, and CAF-driven acinar-to-ductal metaplasia via a LAMA5/ITGA4/STAT3 axis [PMID:28935990, PMID:24068493, PMID:36266324, PMID:31318439, PMID:38154529].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing that VLA-4–VCAM-1 engagement delivers a direct anti-apoptotic signal showed the integrin has a signaling function beyond simple adhesion, as disruption of follicular dendritic cell–B cell contacts with anti-CD49d or anti-VCAM-1 induced germinal center B cell apoptosis while purified VCAM-1 rescued survival.\",\n      \"evidence\": \"mAb-mediated disruption of FDC–B cell clusters and adhesion to immobilized VCAM-1, apoptosis assays in primary human tonsil GC B cells\",\n      \"pmids\": [\"7511659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream survival signaling molecules not identified\", \"Whether β7 pairing can substitute for β1 in this context unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Mapping the ligand-binding determinants to α4 residues 108–268 and β1-Asp130 resolved which structural regions are responsible for dual recognition of VCAM-1 and fibronectin CS-1, establishing that the two ligands share overlapping binding mechanisms.\",\n      \"evidence\": \"Interspecies α4 chimeras, function-blocking mAb epitope mapping, D130A β1 mutagenesis with adhesion assays\",\n      \"pmids\": [\"7531439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of the α4β1–ligand interface not determined\", \"Relative contribution of each epitope to affinity not quantified\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating that monocyte transendothelial migration across activated endothelium can proceed via VLA-4/VCAM-1 independently of CD18 integrins established an alternative adhesion cascade for leukocyte extravasation, with VCAM-1 domains 1 and 4 acting as independent docking sites.\",\n      \"evidence\": \"Domain-specific VCAM-1 blocking mAbs, CD18 and α4 blocking in transendothelial migration assays across CHO-VCAM transfectants and IL-1-activated HUVEC\",\n      \"pmids\": [\"7545712\", \"7542307\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether domain-1 and domain-4 engage the same α4 epitope or distinct sites not resolved\", \"Relative contribution of α4β7 vs. α4β1 in this transmigration not tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showing that VLA-4 ligation activates the phosphoinositide pathway and triggers bidirectional Ca²⁺ signaling between T cells and endothelial cells revealed that VLA-4 engagement initiates classical second-messenger cascades, while the finding that VLA-4 costimulates NF-AT, AP-1, and NF-κB downstream of TCR established its role as a bona fide T cell costimulatory molecule.\",\n      \"evidence\": \"Spectrofluorimetry/confocal Ca²⁺ imaging with Fura-2, IP3 assays in Jurkat cells; EMSA for transcription factors and cytokine ELISA with co-immobilized VCAM-1/CS-1 in primary T cells\",\n      \"pmids\": [\"9209507\", \"8757316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Proximal kinase linking VLA-4 to PLC/IP3 not identified\", \"Whether costimulation requires sustained adhesion or transient ligation not tested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Discovery that tetraspanins CD81, CD82, CD63, and CD53 specifically associate with α4β1 through the ligand-competent extracellular domain of α4—independently of the cytoplasmic tail—revealed a supramolecular organization principle in which tetraspanin-enriched microdomains scaffold integrin signaling platforms.\",\n      \"evidence\": \"Reciprocal co-immunoprecipitation, confocal co-localization, adhesion-deficient α4 mutants (D346E, D408E) and cytoplasmic-tail deletion constructs\",\n      \"pmids\": [\"8757325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of tetraspanin association for downstream signaling not directly tested\", \"Stoichiometry and direct vs. bridged interaction not resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Intrapulmonary anti-CD49d blockade inhibited airway eosinophilia, cytokine release, mucus production, and hyperresponsiveness in allergic mice—while systemic blockade only affected eosinophilia—identifying a CD49d-positive intrapulmonary effector cell as the critical mediator of allergen-induced airway inflammation.\",\n      \"evidence\": \"Intranasal vs. intraperitoneal anti-CD49d mAb in ovalbumin-sensitized mouse model; BAL counts, cytokines, methacholine challenge\",\n      \"pmids\": [\"9399955\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the intrapulmonary CD49d+ effector cell not definitively established\", \"Whether α4β7 contributes in addition to α4β1 not distinguished\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showing that α4β1 and α5β1 mediate β2-integrin-independent neutrophil recruitment to inflamed lung parenchyma via combinatorial mAb blocking expanded the paradigm that β1 integrins serve as an alternative neutrophil emigration pathway in tissue-specific inflammation.\",\n      \"evidence\": \"Intratracheal LPS in rats, myeloperoxidase assay, BAL counts, combined anti-α4/anti-α5/anti-β2 mAb blocking\",\n      \"pmids\": [\"11254723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ligand(s) engaged by α4β1 on pulmonary endothelium/matrix not identified\", \"Kinetics of α4 vs. β2 utilization during disease progression not studied\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that CD49d is required for chemokine-induced neutrophil mobilization from bone marrow—with >75% dependence—while CD18 promotes retention established opposing roles for these integrins in controlling the bone marrow neutrophil reserve.\",\n      \"evidence\": \"In situ perfusion of rat femoral bone marrow with MIP-2, blocking mAbs and CD49d antagonist\",\n      \"pmids\": [\"15542579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific VCAM-1 or other stromal ligand mediating retention not identified\", \"Whether this mechanism applies to other hematopoietic lineages not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of RUNX3 as a transcriptional activator of the ITGA4 promoter provided the first transcription-factor-level explanation for CD49d upregulation during dendritic cell maturation.\",\n      \"evidence\": \"CD49d promoter transactivation assay, RUNX3 overexpression, Northern/RT-PCR in maturing monocyte-derived DCs\",\n      \"pmids\": [\"16164020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RUNX3 binding site in the ITGA4 promoter not mapped by ChIP\", \"Whether RUNX3 is necessary (loss-of-function) not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolving that VCAM-1 module 1 is engaged exclusively by α4β1 while module 4 is engaged by both α4β1 and αMβ2 clarified the molecular basis of module-specific adhesion and revealed PI3K-dependent regulation of the module-4 pathway, with IL-5 shifting integrin usage toward αMβ2.\",\n      \"evidence\": \"Defined VCAM-1 module constructs, mAb blocking, PI3K inhibitors, eosinophilic cell lines lacking αMβ2, primary eosinophils\",\n      \"pmids\": [\"16943205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for module specificity not determined\", \"Whether PI3K acts on integrin activation state or surface expression not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovering that CD38 constitutively associates with CD49d in CLL and enhances VCAM-1 adhesion, Vav-1 phosphorylation, and survival signaling explained the synergistic prognostic impact of CD38+CD49d+ co-expression in CLL.\",\n      \"evidence\": \"Cocapping, co-immunoprecipitation, CD38 transfection into Mec-1 cells, adhesion/apoptosis assays, pVav-1 immunoblot in primary CLL\",\n      \"pmids\": [\"22289918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD38 enzymatic activity is required or just its physical presence not resolved\", \"Structural interface between CD38 and α4β1 unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Elucidating that CD44 and CD49d cooperate through ligand-induced proximity to share downstream kinases (FAK, Src, paxillin, lck→MAPK)—requiring intact cytoplasmic tails of both—and that combined blockade dislodges leukemia cells in vivo, provided a mechanistic framework for adhesion-based therapeutic targeting.\",\n      \"evidence\": \"Mutagenesis of CD49d (FAK-binding/phosphorylation sites) and CD44 (ezrin-binding/tail-truncated) in lymphoma/Jurkat cells, Co-IP, in vivo adhesion/migration assays\",\n      \"pmids\": [\"24127558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural contact between CD44 and CD49d not demonstrated\", \"Relative contribution of each kinase to survival vs. migration not dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that ITGA4 promoter CpG methylation inversely controls CD49d expression—with demethylation rescuing expression—established an epigenetic layer of ITGA4 regulation and linked trisomy 12 CLL to constitutive CD49d overexpression via hypomethylation.\",\n      \"evidence\": \"Bisulfite genomic sequencing, 5-aza-2′-deoxycytidine demethylation rescue, flow cytometry across ~1200 CLL cases\",\n      \"pmids\": [\"24068493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific CpG sites are functionally decisive not narrowed down\", \"Methyltransferase(s) responsible not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying a NOTCH1→NF-κB→CD49d transcriptional axis in CLL explained how gain-of-function NOTCH1 mutations drive CD49d overexpression and the associated aggressive clinical phenotype.\",\n      \"evidence\": \"NOTCH1 intracellular domain stable transfection in MEC-1, NOTCH1/NF-κB pharmacological inhibitors, NF-κB nuclear translocation assay, primary CLL with mutated NOTCH1\",\n      \"pmids\": [\"28935990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NF-κB binds the ITGA4 promoter directly or through intermediary factors not shown\", \"Contribution of non-canonical NF-κB not assessed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showing that BCR signaling triggers VLA-4 inside-out activation through a PI3K-dependent, BTK-independent mechanism—and that ibrutinib reduces but cannot fully suppress this—revealed why CD49d+ CLL may resist BTK-inhibitor therapy through sustained adhesion.\",\n      \"evidence\": \"Inside-out VLA-4 activation assays, ibrutinib treatment, PI3K/BTK inhibitors, in vivo models, three independent clinical CLL cohorts\",\n      \"pmids\": [\"29301866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the PI3K isoform responsible not determined\", \"Whether this mechanism operates in other B cell malignancies not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery that METTL3-mediated m6A methylation stabilizes ITGA4 mRNA, increasing protein expression and AML homing/engraftment, introduced a post-transcriptional regulatory layer and identified METTL3 inhibition as a strategy to target ITGA4-dependent leukemia–niche interactions.\",\n      \"evidence\": \"METTL3 knockdown/overexpression, mRNA stability assays, m6A profiling, in vivo xenograft homing models, METTL3 inhibitor treatment\",\n      \"pmids\": [\"36266324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific m6A site(s) on ITGA4 mRNA not mapped\", \"m6A reader protein mediating stabilization not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of a CAF-secreted LAMA5/ITGA4/STAT3 axis driving acinar-to-ductal metaplasia expanded ITGA4 function beyond immune cell biology into stromal-epithelial crosstalk in early pancreatic carcinogenesis.\",\n      \"evidence\": \"LC-MS/MS proteomics, RNA-seq, ITGA4 knockdown, acinar organoid/explant co-culture, KC and KPC mouse models\",\n      \"pmids\": [\"38154529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ITGA4 pairs with β1 or β7 in acinar cells not specified\", \"Downstream STAT3 targets mediating ADM not identified\", \"Whether ITGA4 blockade prevents tumor progression beyond ADM not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structural model of the full α4β1 ectodomain in complex with VCAM-1 or fibronectin CS-1 remains unresolved, and the precise mechanisms by which tetraspanin and CD38/CD44 supramolecular assemblies organize α4β1 signaling at the nanoscale are still unknown.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No atomic-resolution α4β1–ligand co-structure\", \"Nanoscale organization of the α4β1–tetraspanin–CD38–CD44 signaling platform unresolved\", \"Relative in vivo contributions of α4β1 vs. α4β7 in most tissue contexts not systematically addressed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 6, 7, 11, 13]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 4, 23]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [15, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 3, 11, 16]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 6, 7, 8, 24, 25, 28]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 19, 22, 23]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 6, 11, 13]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 10, 17]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 10, 22]}\n    ],\n    \"complexes\": [\n      \"VLA-4 (α4β1 integrin)\",\n      \"α4β7 integrin\",\n      \"Tetraspanin-enriched microdomain (CD81/CD82/CD63/CD53–α4β1)\"\n    ],\n    \"partners\": [\n      \"ITGB1\",\n      \"ITGB7\",\n      \"VCAM1\",\n      \"CD38\",\n      \"CD44\",\n      \"CD81\",\n      \"CD82\",\n      \"PTK2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}